Growth hormone therapy improved exercise capacity, heart function, and quality of life in patients with HFrEF and growth ...

Patients hospitalized for severe COVID-19 exhibit cardiac systolic dysfunction and small vessel disease at long-term ...

High-resolution computed tomography (HRCT) is the standard to diagnose and assess progression in interstitial lung disease (ILD), a key feature in ...

Global Hemodynamic Monitoring Market valued at $1.04 billion (2021), is set to witness a growth rate of 6% in the next 5 years. Growing cases of cardiovascular diseases, COPD and other respiratory ...

Phosphodiesterase type 5 (PDE5) inhibitors like sildenafil citrate may prevent intrapartum fetal distress. The results contradict an earlier study that indicated benefits with PDE5 inhibitors; further ...

Sickle Cell disease disproportionately affects India’s tribal populations, with complications impacting both children and ...

Regardless of chronic obstructive pulmonary disease status, finerenone mitigates clinical events and symptoms in patients with HFmrEF or HFpEF.

Insmed stock catapulted into breakout territory early Tuesday after the biotech company hit a "home run" with its treatment for PAH.

Doctors and researchers are exploring various approaches to tackle this pervasive health issue, from new medications to dietary interventions. But what if one of the most promising treatments relies ...

Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the ...

A study of HB-1614 suggests it may improve exercise capacity in adults with pulmonary hypertension associated with ...

Panelists discuss how current therapeutic strengths include 15 approved treatments with different mechanisms of action that ...